Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 401 to 425 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
208 occurrence Liver Diseases (MESH:D008107) 139: N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
209 abnormal cell proliferation (GO:0008283) Liver cell (FMA:63179) 854: Alterations, Cellular proliferation / hyperplasia
192 occurrence liver fibrosis (MP:0003333) liver (UBERON:0002107)
536 increased liposarcoma (MESH:D008080) 1036: Increased, liposarcoma
281 decreased lipoprotein transport (GO:0042953) lipoprotein (CHEBI:6495) 643: Decreased Cholesterol, Decreased Uptake of Lipoproteins
446 functional change Lipid bilayer of wall of lysosome (FMA:67514) 829: Damage, Lipid bilayer
971 increased gene expression (GO:0010467) lipid (CHEBI:18059) None
285 increased apoptotic process (GO:0006915) Leydig cell (CL:0000178) 648: Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells
286 abnormal cytoskeleton organization (GO:0007010) Leydig cell (CL:0000178) 649: Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton
390 increased Leydig cell hyperplasia (MP:0001152) Leydig cell (CL:0000178) 744: Increase, Hyperplasia (Leydig cells)
692 increased cell activation involved in immune response (GO:0002263) leukocyte (CL:0000738) 1494: Leukocyte recruitment/activation
902 increased eye opacity (MP:0009859) Lens (FMA:58241) 2083: Occurrence of Cataracts
543 increased leiomyoma (MESH:D007889) 1044: Promotion, mesovarian leiomyomas
823 increased synaptic transmission, glutamatergic (GO:0035249) L-glutamate(1-) (CHEBI:29985) 1350: Increased, glutamate
191 increased macrophage activation (GO:0042116) Kupffer cell (CL:0000091) 134: Increase, Kupffer cell activation
364 increased cell death (GO:0008219) kidney tubule cell (CL:1000507) 709: Increase, Cytotoxicity (renal tubular cell)
368 increased hyperplasia (MESH:D006965) kidney tubule cell (CL:1000507) 767: Increase, Hyperplasia (renal tubular cells)
690 increased epithelial cell proliferation (GO:0050673) kidney tubule cell (CL:1000507) 710: Increase, Regenerative cell proliferation (tubular epithelial cells)
576 occurrence ischemia (MESH:D007511) kidney (UBERON:0002113) 1105: Occurrence, renal ischemia
439 decreased function (MI:0613) kidney (UBERON:0002113) 825: Decreased, Renal ability to dilute urine
442 occurrence toxicity (MESH:Q000633) kidney (UBERON:0002113) 814: Occurrence, Kidney toxicity
29 abnormal ketone body (CHEBI:73693) 862: Not Increased, Circulating Ketone Bodies
655 increased signaling (GO:0023052) juvenile hormone (CHEBI:24943) 1205: Activation, Juvenile hormone receptor
681 increased signaling (GO:0023052) JNK Mitogen-Activated Protein Kinases (MESH:D048031) 1292: Activation, JNK
671 increased signaling (GO:0023052) Janus kinase (PR:000025748) 1282: Activation, JAK/STAT pathway